Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Veru Inc. (VERU)

15.6   2.1 (15.56%) 05-18 02:09
Open: 12.93 Pre. Close: 13.5
High: 15.75 Low: 12.76
Volume: 50,470,086 Market Cap: 1,249(M)
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 15.76 - 15.81 15.81 - 15.86
Low: 12.64 - 12.69 12.69 - 12.74
Close: 15.5 - 15.59 15.59 - 15.68

Technical analysis

as of: 2022-05-17 4:51:02 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 20.44     One year: 23.87
Support: Support1: 10.88    Support2: 6.79
Resistance: Resistance1: 17.5    Resistance2: 20.44
Pivot: 10.56
Moving Average: MA(5): 11.85     MA(20): 11.03
MA(100): 6.98     MA(250): 7.6
MACD: MACD(12,26): 0.9     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 82.3     %D(3): 58.4
RSI: RSI(14): 68.5
52-week: High: 17.5  Low: 4.34
Average Vol(K): 3-Month: 22,841 (K)  10-Days: 29,005 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ VERU ] has closed It is unclear right now based on current values. 153.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 25 days. This is a sign that the current trend might continue.

Headline News

Tue, 17 May 2022
So What's Up With Veru Shares Rising Today? - Benzinga - Benzinga

Tue, 17 May 2022
Catch Fast-Moving Veru Stock as Covid-19 Drug Results Show Promise - InvestorPlace

Tue, 17 May 2022
Veru: Where Big Pharma Failed To Tread - Seeking Alpha

Tue, 17 May 2022
Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022 - Yahoo Finance

Mon, 16 May 2022
How Is The Market Feeling About Veru? - Benzinga - Benzinga

Fri, 13 May 2022
BioMed Stocks On the Move: Nova Mentis, PolarityTE, Veru, and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, Novel Therapeutics for Oncology, COVID, Glaucoma, and Autism - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 80 (M)
Shares Float 60 (M)
% Held by Insiders 19.5 (%)
% Held by Institutions 30.8 (%)
Shares Short 2,660 (K)
Shares Short P.Month 2,300 (K)

Stock Financials

EPS 0.09
EPS Est Next Qtl 0
EPS Est This Year -0.18
EPS Est Next Year -0.08
Book Value (p.s.) 1.89
Profit Margin (%) 12
Operating Margin (%) -8.9
Return on Assets (ttm) -3
Return on Equity (ttm) 8.1
Qtrly Rev. Growth 33.2
Gross Profit (p.s.) 0.59
Sales Per Share 0.76
EBITDA (p.s.) -0.07
Qtrly Earnings Growth 0
Operating Cash Flow -16 (M)
Levered Free Cash Flow -13 (M)

Stock Valuations

PE Ratio 173.33
PEG Ratio -0.2
Price to Book value 8.21
Price to Sales 20.37
Price to Cash Flow -80.19

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2014-05-06
Ex-Dividend Date 2014-04-27
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.